Array BioPharma and Pierre Fabre announce COLUMBUS phase 3 study met primary endpoint
Array BioPharma and Pierre Fabre announced top-line results from Part 1 of the Phase 3 COLUMBUS study evaluating LGX818 (encorafenib), a BRAF inhibitor, and MEK162 (binimetinib), a MEK inhibitor, in patients with BRAF-mutant advanced, metastatic melanoma. The study met its primary endpoint. September 26, 2016